A calcium-sensing MCTP1/FYN/MEF2C circuit drives therapy-induced neuroendocrine prostate cancer.

Saved in:
Bibliographic Details
Title: A calcium-sensing MCTP1/FYN/MEF2C circuit drives therapy-induced neuroendocrine prostate cancer.
Authors: Dung PVT; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City 235, Taiwan., Chen WY; Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan; Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan., Liu MK; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City 235, Taiwan., Yeh SD; Department of Urology and Oncology, Taipei Medical University Hospital, Taipei 11031, Taiwan; Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan; Prostate Center of Excellence, Taipei Medical University Hospital, Taipei 11031, Taiwan., Kajla G; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City 235, Taiwan., Yeh HL; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City 235, Taiwan., Chen WH; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City 235, Taiwan., Jiang KC; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City 235, Taiwan., Li HR; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City 235, Taiwan., Chen CS; School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan., Beltran H; Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215-5450, USA., Wen YC; Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan; Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan; TMU Research Center of Urology and Kidney, Taipei Medical University, Taipei 11031, Taiwan. Electronic address: 95207@w.tmu.edu.tw., Liu YN; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City 235, Taiwan; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City 235, Taiwan; Prostate Center of Excellence, Taipei Medical University Hospital, Taipei 11031, Taiwan. Electronic address: liuy@tmu.edu.tw.
Source: Neoplasia (New York, N.Y.) [Neoplasia] 2026 Jan; Vol. 71, pp. 101251. Date of Electronic Publication: 2025 Nov 01.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100886622 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5586 (Electronic) Linking ISSN: 14765586 NLM ISO Abbreviation: Neoplasia Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5586
DOI:10.1016/j.neo.2025.101251